Duavee is an osteoporosis prevention and menopause treatment drug owned by Wyeth Pharms, which first came to market on October 3, 2013. This medication contains Bazedoxifene Acetate and Estrogens, Conjugated, and is available in tablet form for oral administration. Duavee holds a total of 2 patents, both of which are still active.
The very first generic versions of Duavee might become available after March 10, 2027, which marks the expiration date of its last patent. This release date does not account for potential legal complications or additional patents. Improvements or changes to the drug, such as new delivery methods or dosage forms, could extend Duavee's patent protection.
Duavee is primarily used for the prevention of postmenopausal osteoporosis and the treatment of moderate to severe vasomotor symptoms, which are commonly associated with menopause. The drug's effectiveness comes from its active ingredients, Bazedoxifene Acetate and Estrogens, Conjugated. Bazedoxifene is used to reduce the risk of endometrial hyperplasia, while the estrogens help manage menopause symptoms and prevent osteoporosis.
Duavee holds two patents: US6479535, which expires on May 6, 2024, and US7683051, which will extend Duavee's exclusive marketing rights until March 10, 2027. Changes in delivery methods, dosage forms, or improvements could potentially delay the release of Duavee generics. Below are the details of the patent: